altitude sickness treatment
Phase 2- Indications
- Pulmonary arterial hypertension, Altitude sickness
Company intelligence / Profile preview
Shijiazhuang Sagacity New Drug Development Co., Ltd.
Shijiazhuang, Hebei, Chinachictr.org.cn ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
SC0191, a small molecule inhibitor of Wee1 kinase, has demonstrated excellent antitumor efficacy in TP53 mutant solid cancer preclinical studies, showing better results than AZD1775 in NCI-H446 and BxPC-3 CDX mouse models[4].
- Therapeutic areas
- OtherOncologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Shijiazhuang Sagacity New Drug Development Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shijiazhuang Sagacity New Drug Development Co., Ltd..